The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Open accessAbstract
Purpose: Ameloblastoma is an odontogenic neoplasm whose overall mutational landscape has not been well characterized. We sought to characterize pathogenic mutations in ameloblastoma and their clinical and functional significance with an emphasis on the mitogen-activated protein kinase (MAPK) pathway. Experimental Design: A total of 84 ameloblastomas and 40 non-ameloblastoma odontogenic tumors were evaluated with a combination of BRAF V600E allele–specific PCR, VE1 immunohistochemistry, the Ion AmpliSeq Cancer Hotspot Panel, and Sanger sequencing. Efficacy of a BRAF inhibitor was evaluated in an ameloblastoma-derived cell line. Results: Somatic, activating, and mutually exclusive RAS–BRAF and FGFR2 mutations were identified in 88% of cases. Somatic mutations in SMO, CTNNB1, PIK3CA, and SMARCB1 were also identified. BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in ameloblastic fibromas/fibrodentinomas but not in other odontogenic tumors. This mutation was associated with a younger age of onset, whereas BRAF wild-type cases arose more frequently in the maxilla and showed earlier recurrences. One hundred percent concordance was observed between VE1 immunohistochemistry and molecular detection of BRAF V600E mutations. Ameloblastoma cells demonstrated constitutive MAPK pathway activation in vitro. Proliferation and MAPK activation were potently inhibited by the BRAF inhibitor vemurafenib. Conclusions: Our findings suggest that activating FGFR2–RAS–BRAF mutations play a critical role in the pathogenesis of most cases of ameloblastoma. Somatic mutations in SMO, CTNNB1, PIK3CA, and SMARCB1 may function as secondary mutations. BRAF V600E mutations have both diagnostic and prognostic implications. In vitro response of ameloblastoma to a BRAF inhibitor suggests a potential role for targeted therapy. Clin Cancer Res; 20(21); 5517–26. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,453
Activating Smoothened mutations in sporadic basal-cell carcinoma
Xie, J., Murone, M., Luoh, S.-M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C.-W., Hynes, M., Goddard, A., et al. (1998) · Nature · doi:10.1038/34201 · Cited by 1,334
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“Thismutation is present innumerous neoplasms, including melanoma (12), hairy cell leukemia (13), papillary thyroid carcinoma (14), Langerhans cell histiocytosis (15), and colorectal cancer (16).”
BackgroundInhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog
Stone, D. M., Hynes, M., Armanini, M., Swanson, T. A., Gu, Q., Johnson, R. L., Scott, M. P., Pennica, D., Goddard, A., Phillips, H., et al. (1996) · Nature · doi:10.1038/384129a0 · Cited by 1,106
BRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024
Genomic Analysis of Non- NF2 Meningiomas Reveals Mutations in TRAF7 , KLF4 , AKT1 , and SMO
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Özduman, K., Avşar, T., Li, J., Murray, P. B., Henegariu, O., et al. (2013) · Science · doi:10.1126/science.1233009 · Cited by 912
Cited by
Wright, J. M., & Vered, M. (2017) · Head and Neck Pathology · doi:10.1007/s12105-017-0794-1 · Cited by 681
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 390
Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., Féliz, L., Zecchetto, C., Melisi, D., & Burn, T. C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0766 · Cited by 283
Metadata
- Authors
- Brown, N. A., Rolland, D., McHugh, J. B., Weigelin, H. C., Zhao, L., Lim, M. S., Elenitoba-Johnson, K. S. J., & Betz, B. L.
- Venue
- Clinical Cancer Research
- Published
- 2014-10-30
- Volume
- 20
- Issue
- 21
- Pages
- 5517-5526
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2164666147
- Cited by
- 298
- References
- 36
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1069
- The paper
- Brown, N. A., Rolland, D., McHugh, J. B., Weigelin, H. C., Zhao, L., Lim, M. S., Elenitoba-Johnson, K. S. J., & Betz, B. L. (2014). Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.